targeting of ebv containing cells by increasing the expression of monoclonal antibody reactive antigen greiner et al science 235 895 1987 alternatively the monoclonal antibody of the invention could be used for example in combination with gamma interferon to thereby activate and increase the expression of fc receptors by effector cells which in turn results in an enhanced binding of the monoclonal antibody to the effector cell and killing of target tumor cells those of skill in the art will be able to select from the various biological response modifiers to create a desired effector function which enhances the efficacy of the monoclonal antibody of the invention when the monoclonal antibody of the invention is used in combination with various therapeutic agents such as those described herein the administration of the monoclonal antibody and the therapeutic agent usually occurs substantially contemporaneously the term u201c substantially contemporaneously u201d means that the monoclonal antibody and the therapeutic agent are administered reasonably close together with respect to time usually it is preferred to administer the therapeutic agent before the monoclonal antibody for example the therapeutic agent can be administered 1 to 6 days before the monoclonal antibody the administration of the therapeutic agent can be daily or at any other interval depending upon such factors for example as the nature of the.